MedPath

Role Prophylactic nitrofurantoin in preventing urinary infection after routine cystocopy

Not Applicable
Conditions
Health Condition 1: N390- Urinary tract infection, site notspecified
Registration Number
CTRI/2019/11/022022
Lead Sponsor
niversity College of Medical Sciences University of Delhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients undergoing routine office rigid

cystoscopy of age between 18-80yrs.

2.Patients undergoing cystoscopy for ureteral JJ

stent removal.

Exclusion Criteria

1.Patients with symptoms of active/untreated

UTI.

2.Patients showing growth in urine culture done

prior to cystoscopy.

3.High risk patients-DM,Immunosuppressed,CKD

etc,

4.Patients with indwelling urethral catheters/

stricture urethra undergoing manipulation/

OIU.

5.Patients with hypersensitivity and or any

contraindications to nitrofurantoin.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy Criteria: (i) Urine c/s positive at 48hrs,7d, 2wks (primary endpoint) i.e. Urine culture of 100,000 CFU/mL urine. (Objective) & (ii) S/s and positive LET of UTI (Subjective) at 48hrs/7days/2weeks. The primary outcome will be development of urinary tract infection (UTI) within 2 weeks after cystoscopy.Timepoint: 48 hrs, 7d, 14d
Secondary Outcome Measures
NameTimeMethod
Criteria for safety will be (i) by monitoring TEAE of NFT as per performa (ADE, ADR, SE, SAE). Criteria for Morbidity will be (i) VAS pain score at 1hour post CPE and (ii) Clavein Dindo grade of complications including symptomatic gross hematuria within 24 hrs.Timepoint: 1hrs, 24hrs, 48hrs, 7d, 14d
© Copyright 2025. All Rights Reserved by MedPath